The Administrative Part of Core A provides Dr. Schreiber protected time for scientific leadership and carefulguidance of the Program Project. This leadership will be essential for achieving the goals of the programproject that depend on integrating scientists with highly complementary but fundamentally different skills andoperation modes and very diverse methodology and technology. Effective productive integration will dependon minimizing negative effects of the physical separation of the interacting scientists. This requiresdedicated time from Dr. Schreiber for careful planning and using methods of easy interaction over longdistances. For coordinating the scientific and technical activities of this program project, the Core will (i)organize a monthly steering committee meeting and research-in-progress meeting with the leaders of thefour projects, the statistician and the core directors with careful planning of the agenda including distributionof data, manuscripts and papers to be discussed, (ii) organizes a more comprehensive quarterly meeting ofall scientific and technical personnel involved in the program, (iii) prepare, distribute and maintain electronicfiles of reports, protocols and images and distribute relevant research articles, (iv) prepare and updateexisting databases for cell lines, gene constructs, monoclonal antibodies and vectors, and (v) monitor day-todayexpenses, support and organize the visits of one external scientific advisor and one external collaboratorper year. The Statistics Part of Core A, provides a protected time to our statistician Dr. Karrison. Thisprovides researchers with a highly experienced scholarly statistician who is dedicated to the success of thisprogram project. This arrangement will give us much improved access to biostatistical consultation duringthe planning and execution and analysis stages of the proposed studies. The Imaging Part of Core A underthe leadership of Dr. P. Charles Lin provides researchers with continued access to the first rate imaginginstitute at Vanderbilt for optical imaging using window chamber technology. The migration and localizationof the fluorescent T cells or fluorochrome-tagged molecules to large well-established tumors will bemonitored through a window opening on one side of these tumors using the Zeiss multiphoton laserscanning microscope LSM 510 META. The new META (Zeiss) spectral detectors resolve emissions fromthese different fluorescent dyes efficiently and exactly by providing linear spectral unmixing using specializedsoftware. The microscopic imaging of the tumor microenvironment will give us detailed information on realtime events and precise locality of cells or molecules injected into mice in the various models proposed.
| Tang, Haidong; Zhu, Mingzhao; Qiao, Jian et al. (2017) Lymphotoxin signalling in tertiary lymphoid structures and immunotherapy. Cell Mol Immunol 14:809-818 |
| Arina, Ainhoa; Karrison, Theodore; Galka, Eva et al. (2017) Transfer of Allogeneic CD4+ T Cells Rescues CD8+ T Cells in Anti-PD-L1-Resistant Tumors Leading to Tumor Eradication. Cancer Immunol Res 5:127-136 |
| Kammertoens, Thomas; Friese, Christian; Arina, Ainhoa et al. (2017) Tumour ischaemia by interferon-? resembles physiological blood vessel regression. Nature 545:98-102 |
| Arina, Ainhoa; Idel, Christian; Hyjek, Elizabeth M et al. (2016) Tumor-associated fibroblasts predominantly come from local and not circulating precursors. Proc Natl Acad Sci U S A 113:7551-6 |
| Blankenstein, Thomas; Leisegang, Matthias; Uckert, Wolfgang et al. (2015) Targeting cancer-specific mutations by T cell receptor gene therapy. Curr Opin Immunol 33:112-9 |
| Smith, Sheena N; Harris, Daniel T; Kranz, David M (2015) T Cell Receptor Engineering and Analysis Using the Yeast Display Platform. Methods Mol Biol 1319:95-141 |
| Corrales, Leticia; Glickman, Laura Hix; McWhirter, Sarah M et al. (2015) Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. Cell Rep 11:1018-30 |
| Gajewski, Thomas F; Corrales, Leticia (2015) New perspectives on type I IFNs in cancer. Cytokine Growth Factor Rev 26:175-8 |
| Spaapen, Robbert M; Leung, Michael Y K; Fuertes, Mercedes B et al. (2014) Therapeutic activity of high-dose intratumoral IFN-? requires direct effect on the tumor vasculature. J Immunol 193:4254-60 |
| Woo, Seng-Ryong; Fuertes, Mercedes B; Corrales, Leticia et al. (2014) STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 41:830-42 |
Showing the most recent 10 out of 104 publications
